SFRP5 and metabolic dysfunction-associated steatohepatitis: We reported increased expression of hepatic mRNA SFRP5 in NAFLD patients than NL ones; and then, when we classified our NAFLD subjects in SS and NASH, we observed higher expression in the SS group than NL and also than NASH patients.